Confo Therapeutics

Confo Therapeutics is a clinical-stage biotechnology company developing novel GPCR-directed medicines for metabolic and endocrine diseases. Its proprietary Confo® technology uses specialized camelid single-domain antibodies to stabilize G-protein-coupled receptors and support drug discovery. The company builds its own pipeline of therapeutic programs, including small-molecule and antibody-based treatments, while also partnering with pharmaceutical companies on selected GPCR targets for patients with significant unmet medical needs.